Literature DB >> 7837144

Pleural fluid soluble interleukin 2 receptor in rheumatoid arthritis and systemic lupus erythematosus.

T Pettersson1, T Söderblom, P Nyberg, H Riska, L Linko, M Klockars.   

Abstract

OBJECTIVE: To study local cellular immune reactions in the pleural fluid of patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
METHODS: Using an immunoenzymometric assay, the concentration of soluble interleukin 2 receptor (sIL-2R) was measured in the pleural fluid of 13 patients with RA, 6 patients with SLE and 72 patients with pleural effusions of other etiologies, including tuberculosis, cancer, pneumonia and congestive heart failure.
RESULTS: The mean pleural fluid sIL-2R concentration was significantly higher in patients with RA (593 pM, range 252-1558) than in patients with SLE (145 pM, range 94-236; p < 0.005), cancer (224 pM, range 98-521, p < 0.01), pneumonia (177 pM, range 60-343, p < 0.005) and congestive heart failure (139 pM, range 56-228, p < 0.005), but as high in patients with tuberculous pleurisy (mean 390 pM, range 151-512). The highest mean pleural fluid to serum sIL-2R ratios were observed in patients with RA and with tuberculosis.
CONCLUSION: Measurement of sIL-2R in pleural fluid is useful for the differentiation of pleural effusions in RA from those occurring in SLE. High levels of sIL-2R associated with a local T cell mediated immune reaction may serve an immunoregulatory purpose in rheumatoid pleurisy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7837144

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan.

Authors:  Peter Durda; Jeremy Sabourin; Ethan M Lange; Mike A Nalls; Josyf C Mychaleckyj; Nancy Swords Jenny; Jin Li; Jeremy Walston; Tamara B Harris; Bruce M Psaty; William Valdar; Yongmei Liu; Mary Cushman; Alex P Reiner; Russell P Tracy; Leslie A Lange
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-20       Impact factor: 8.311

Review 2.  Advances in interleukin 2 receptor targeted treatment.

Authors:  J C Morris; T A Waldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.

Authors:  Vincenzo Quagliariello; Annamaria Bonelli; Antonietta Caronna; Gabriele Conforti; Martina Iovine; Andreina Carbone; Massimiliano Berretta; Gerardo Botti; Nicola Maurea
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.